About Hindustan Bio Sciences Limited
Hindustan Bio Sciences Limited is a publicly listed company based in Hyderabad (India) founded in 2000. Hindustan Bio Sciences Limited is engaged in pharmaceutical and biotechnology operations. It operates on a Direct-to-Consumer (D2C) and Reseller / Distribution model. Its Indian entity Hindustan Bio Sciences Limited reported revenue of ₹81.3 Lakh. Hindustan Bio Sciences Limited offers products and services including Tablets, Capsules, Drops, Syrups, and Externels. Its focus areas include Pharmaceuticals, Drug Manufacturing, Biotechnology and Biotech Products. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Hindustan Bio Sciences Limited (HBSL) is involved in diversified operations within the pharmaceutical and biotechnology sectors. The company is equipped with world-class manufacturing facilities for a wide range of products, including dry and liquid injectables, syrups, eyeearnasal drops, pre-filled syringes, and various ointments, tablets, and capsules. These facilities are approved by several regulatory authorities and are trusted by healthcare professionals and patients globally. The firm is committed to excellence through innovative approaches, safety, social responsibility, and continuous improvement in its conduct across the healthcare industry.
- Headquarters Hyderabad, India
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website hindustanbiosciences.in
- Legal Name Hindustan Bio Sciences Limited
- Market Cap₹6.94 Cr
HINDBIO · BSE
- Share Price₹6.98
+3.10% today
- Revenue₹0.74 Cr
FY 2025-26 · -8.6% YoY
- EBITDA−₹0.06 Cr
Margin -8.1%
- Net Profit−₹0.08 Cr
FY 2025-26 · -180.0% YoY
Associated legal entities of Hindustan Bio Sciences Limited
Hindustan Bio Sciences Limited is associated with 2 registered companies on The Company Check; the primary company is Hindustan Bio Sciences Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Hindustan Bio Sciences Limited Listed CIN L26942TG1991PLC013564 | Active | 16 Dec 1991 | Hyderabad, Telangana | ₹0.8 Cr | 8 | View details | |
| Consolidated Energy Consultants Limited CIN U74210MP1990PLC005688 | Active | 31 Jan 1990 | Bhopal, Madhya Pradesh | ₹1.1 Cr | 15 | 5 | View details |
Products & Services of Hindustan Bio Sciences Limited
Hindustan Bio Sciences Limited offers a comprehensive portfolio of products and services, including Tablets, Capsules, Drops, Syrups, and Externels.
Tablets are manufactured for various medical treatments globally.
Capsules are produced for diverse therapeutic applications worldwide.
Drops are formulated for eye, ear, nasal use.
Syrups are developed for liquid medicinal intake solutions.
Externels are created for topical medical application needs.
Board of directors of Hindustan Bio Sciences Limited (Hindustan Bio Sciences Limited)
Hindustan Bio Sciences Limited is the primary company behind Hindustan Bio Sciences Limited. The boards of the 2 registered companies of Hindustan Bio Sciences Limited currently have 11 directors; the longest-serving is Manan Kumar Deb, appointed in 1990. 16 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manan Kumar Deb DIN 00102486 | Director | 31 Jan 1990 | 36 yrs 8 mo | Consolidated Energy Consultants Limited |
| Rajan Deb DIN 00102241 | Managing Director | 01 Oct 1994 | 32 yrs | Consolidated Energy Consultants Limited |
| Venkata Rama Mohan Raju Jampana DIN 00060800 | Managing Director | 10 Jun 2000 | 26 yrs 4 mo | Hindustan Bio Sciences Limited |
| Ghanshyam Das Agarwal DIN 01106495 | Director | 27 Nov 2004 | 21 yrs 10 mo | Consolidated Energy Consultants Limited |
| Vibhuti Jha DIN 00396873 | Director | 27 Nov 2004 | 21 yrs 10 mo | Consolidated Energy Consultants Limited |
| Uma Jampana DIN 00912376 | Director | 30 Oct 2007 | 18 yrs 11 mo | Hindustan Bio Sciences Limited |
| Sayan Deb DIN 10135775 | Whole-time director | 04 May 2023 | 3 yrs 5 mo | Consolidated Energy Consultants Limited |
| Jaison George DIN 00502736 | Director | 31 Oct 2023 | 2 yrs 11 mo | Hindustan Bio Sciences Limited |
| Reji Abraham DIN 03321887 | Director | 31 Oct 2023 | 2 yrs 11 mo | Hindustan Bio Sciences Limited |
| Nagi Reddy Bodeddula DIN 02928753 | Director | 30 Sep 2024 | 2 yrs | Hindustan Bio Sciences Limited |
| Pratheek Reddy Gorrela DIN 06534989 | Director | 30 Sep 2024 | 2 yrs | Hindustan Bio Sciences Limited |
IPO & Listings of Hindustan Bio Sciences Limited
Hindustan Bio Sciences Limited is a publicly listed company on the BSE with ticker symbol HINDBIO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onBSE: HINDBIO
- Listed entityHindustan Bio Sciences Limited
- Exchange sectorHealth technology
- ISININE597C01021
- Share price₹6.92 (-4.55% on the day) · 2026-10-14
- Market capitalisation₹7.4 Cr
- Price to earnings269.8
- EPS (diluted, trailing year)₹-0.20
- Volume (last session)12,382
Financials of Hindustan Bio Sciences Limited
Exchange-reported figures of Hindustan Bio Sciences Limited, the listed company behind Hindustan Bio Sciences Limited (BSE: HINDBIO).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.74 | 0.81 | 1.05 | 0.92 | 0.43 | 1.03 | 1.94 |
| Revenue growth | -8.6% | -22.9% | +14.1% | +114.0% | -58.3% | -46.9% | - |
| EBITDA | (0.06) | 0.10 | 0.06 | (0.03) | (0.50) | (0.95) | 0.13 |
| EBITDA margin | -8.1% | +12.4% | +5.7% | -3.3% | -116.3% | -92.2% | +6.7% |
| Profit before tax | (0.08) | 0.10 | 0.05 | (0.04) | (0.50) | (0.97) | 0.11 |
| Net profit | (0.08) | 0.10 | 0.05 | (0.04) | (0.50) | (0.95) | 0.07 |
| Net profit margin | -10.8% | +12.4% | +4.8% | -4.4% | -116.3% | -92.2% | +3.6% |
| EPS (₹) | (0.08) | 0.10 | 0.06 | (0.20) | (0.50) | (0.92) | 0.08 |
| Balance sheet | |||||||
| Total assets | 3.18 | 3.41 | 3.36 | 3.20 | 2.95 | 3.16 | 4.84 |
| Net worth | 0.83 | 0.90 | 0.80 | 0.75 | 0.79 | 1.30 | 2.24 |
| Total debt | 2.35 | 2.51 | 2.56 | 2.46 | 2.17 | 1.86 | 2.60 |
| Cash & bank | 0.13 | 0.01 | 0.04 | 0.01 | 0.01 | 0.02 | 0.20 |
| Net working capital | 0.75 | 0.98 | 0.94 | 0.76 | 0.53 | 0.73 | 1.59 |
| Cash flow | |||||||
| Cash from operations | 0.28 | 0.03 | (1.41) | (0.05) | (0.34) | 0.75 | 0.82 |
| Cash from investing | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from financing | (0.16) | (0.05) | 1.43 | 0.05 | 0.34 | (0.93) | (0.81) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.38 | 0.00 | 0.32 | 0.38 | 0.00 | 0.41 |
| Revenue growth (YoY) | -100.0% | -100.0% | - | -100.0% | -22.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
| Total expenses | 0.11 | 0.11 | 0.31 | 0.06 | 0.32 | 0.28 | 0.04 | 0.34 |
| EBITDA | (0.11) | (0.11) | 0.07 | (0.06) | 0.00 | 0.10 | (0.04) | 0.07 |
| EBITDA margin | - | - | +18.4% | - | 0.0% | +26.3% | - | +17.1% |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.11) | (0.11) | 0.08 | (0.05) | 0.01 | 0.11 | (0.04) | 0.08 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.38 | 0.00 | 0.32 | 0.38 | 0.00 | 0.41 |
| Revenue growth (YoY) | -100.0% | -100.0% | - | -100.0% | -22.0% | - | - | - |
| Other income | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
| Total expenses | 0.11 | 0.11 | 0.31 | 0.06 | 0.32 | 0.28 | 0.04 | 0.34 |
| EBITDA | (0.11) | (0.11) | 0.07 | (0.06) | 0.00 | 0.10 | (0.04) | 0.07 |
| EBITDA margin | - | - | +18.4% | - | 0.0% | +26.3% | - | +17.1% |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.11) | (0.11) | 0.08 | (0.05) | 0.01 | 0.11 | (0.04) | 0.08 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.74 | 0.81 | 1.05 | 0.92 | 0.43 | 1.03 | 1.94 |
| Revenue growth | -8.6% | -22.9% | +14.1% | +114.0% | -58.3% | -46.9% | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.80 | 0.71 | 0.99 | 0.95 | 0.93 | 1.98 | 1.81 |
| Employee cost | 0.00 | 0.07 | 0.09 | 0.18 | 0.18 | 0.19 | 0.20 |
| EBITDA | (0.06) | 0.10 | 0.06 | (0.03) | (0.50) | (0.95) | 0.13 |
| EBITDA margin | -8.1% | +12.4% | +5.7% | -3.3% | -116.3% | -92.2% | +6.7% |
| Depreciation | 0.02 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Profit before tax | (0.08) | 0.10 | 0.05 | (0.04) | (0.50) | (0.97) | 0.11 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | 0.04 |
| Net profit | (0.08) | 0.10 | 0.05 | (0.04) | (0.50) | (0.95) | 0.07 |
| Net profit margin | -10.8% | +12.4% | +4.8% | -4.4% | -116.3% | -92.2% | +3.6% |
| EPS (₹) | (0.08) | 0.10 | 0.06 | (0.20) | (0.50) | (0.92) | 0.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 2.05 | 2.05 | 2.05 | 2.05 | 10.25 | 10.25 | 10.25 |
| Reserves & surplus | (1.22) | (1.15) | (1.25) | (1.30) | (9.46) | (8.95) | (8.01) |
| Shareholders' funds (net worth) | 0.83 | 0.90 | 0.80 | 0.75 | 0.79 | 1.30 | 2.24 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 2.35 | 2.51 | 2.56 | 2.46 | 2.17 | 1.86 | 2.60 |
| Total debt | 2.35 | 2.51 | 2.56 | 2.46 | 2.17 | 1.86 | 2.60 |
| Total liabilities | 3.18 | 3.41 | 3.36 | 3.20 | 2.95 | 3.16 | 4.84 |
| Assets | |||||||
| Gross block | 0.27 | 0.55 | 0.55 | 0.55 | 0.55 | 0.54 | 0.54 |
| Net block | 0.01 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.34 |
| Sundry debtors | 0.05 | 0.44 | 0.44 | 0.45 | 0.14 | 0.62 | 1.36 |
| Cash & bank balances | 0.13 | 0.01 | 0.04 | 0.01 | 0.01 | 0.02 | 0.20 |
| Loans & advances | 0.59 | 0.54 | 0.47 | 0.39 | 0.40 | 0.41 | 0.41 |
| Total current assets | 0.77 | 0.99 | 0.95 | 0.85 | 0.55 | 1.05 | 2.31 |
| Total current liabilities | 0.02 | 0.01 | 0.01 | 0.09 | 0.02 | 0.32 | 0.72 |
| Net working capital | 0.75 | 0.98 | 0.94 | 0.76 | 0.53 | 0.73 | 1.59 |
| Total assets | 3.18 | 3.41 | 3.36 | 3.20 | 2.95 | 3.16 | 4.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.01 | 0.04 | 0.01 | 0.01 | 0.02 | 0.20 | 0.18 |
| Net cash from operating activities | 0.28 | 0.03 | (1.41) | (0.05) | (0.34) | 0.75 | 0.82 |
| Net cash from investing activities | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net cash from financing activities | (0.16) | (0.05) | 1.43 | 0.05 | 0.34 | (0.93) | (0.81) |
| Net change in cash | 0.12 | (0.02) | 0.03 | 0.00 | (0.01) | (0.18) | 0.01 |
| Closing cash | 0.13 | 0.01 | 0.04 | 0.01 | 0.01 | 0.02 | 0.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -8.6% | -22.9% | +14.1% | +114.0% | -58.3% | -46.9% | - |
| EBITDA growth | -160.0% | +66.7% | +300.0% | +94.0% | +47.4% | -830.8% | - |
| PBT growth | - | +100.0% | +9998.0% | +92.0% | +48.5% | - | +10.0% |
| Net income growth | -180.0% | +100.0% | +225.0% | +92.0% | +47.4% | -1457.1% | - |
| Revenue CAGR (3Y) | -7.0% | +23.5% | +0.6% | -22.0% | -50.6% | 0.0% | +24.3% |
| EBITDA CAGR (3Y) | +26.0% | - | - | - | - | -26.1% | - |
| Profitability & leverage | |||||||
| Net income margin | -10.8% | +12.4% | +4.8% | -4.4% | -116.3% | -92.2% | +3.6% |
| Return on capital employed | - | +2.2% | +1.5% | 0.0% | 0.0% | 0.0% | +1.0% |
| Return on net worth | - | +4.9% | +4.3% | 0.0% | 0.0% | 0.0% | +0.8% |
| Debt / equity | - | 2.98 | 3.24 | 3.01 | 1.93 | 1.26 | 1.36 |
| Long-term debt / equity | - | 2.98 | 2.38 | 1.43 | 0.87 | 0.68 | 0.94 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.04 | 8.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.47 | 1.91 | 1.67 | 0.79 | 1.91 | 3.59 |
| Inventory turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 6.06 | 8.62 |
| Debtors turnover | - | 1.84 | 2.36 | 3.12 | 1.13 | 1.04 | 1.28 |
| EPS (₹) | (0.08) | 0.10 | 0.06 | (0.20) | (0.50) | (0.92) | 0.08 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 0.88 | 0.78 | 3.64 | 0.77 | 1.27 | 2.19 |
Similar companies to Hindustan Bio Sciences Limited
Hindustan Bio Sciences Limited has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Hindustan Bio Sciences Limited
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hindustan Bio Sciences Limited
Complete news archive for Hindustan Bio Sciences Limited
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hindustan Bio Sciences Limited
Hindustan Bio Sciences Limited was founded in 2000.
Hindustan Bio Sciences Limited is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
The primary company behind Hindustan Bio Sciences Limited, Hindustan Bio Sciences Limited, reported revenue of ₹81.3 Lakh for FY 2025, down 23% year on year.
Hindustan Bio Sciences Limited (HBSL) is involved in diversified operations within the pharmaceutical and biotechnology sectors. The company is equipped with world-class manufacturing facilities for a wide range of products, including dry and liquid injectables, syrups, eyeearnasal drops, pre-filled syringes, and various ointments, tablets, and capsules. These facilities are approved by several regulatory authorities and are trusted by healthcare professionals and patients globally. The firm is committed to excellence through innovative approaches, safety, social responsibility, and continuous improvement in its conduct across the healthcare industry.
Hindustan Bio Sciences Limited's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Hindustan Bio Sciences Limited offers Tablets, Capsules, Drops, Syrups, and Externels.
Yes, Hindustan Bio Sciences Limited is publicly traded on BSE under the ticker symbol HINDBIO.
Hindustan Bio Sciences Limited is associated with 2 legal entities: Hindustan Bio Sciences Limited, Consolidated Energy Consultants Limited.
The legal entities of Hindustan Bio Sciences Limited currently have 12 directors, including Ghanshyam Das Agarwal, Vibhuti Jha, Rajan Deb and others.